UTHR (United Therapeutics) Other Current Assets: $228 Mil (As of Mar. 2026)


UTHR United Therapeutics Corp UTHR
85 GF Score
Price $547.25
GF Value $386.77
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is United Therapeutics Other Current Assets?

United Therapeutics UTHR -1.56% 85 Other Current Assets is $228 Mil as of Mar. 2026. GuruFocus rates UTHR with a GF Score™ of 85/100 and a GF Value™ of $386.77 (Significantly Overvalued). The stock has 7 warning signs investors should review.

United Therapeutics's other current assets for the quarter that ended in Mar. 2026 was $228 Mil.

United Therapeutics's quarterly other current assets declined from Sep. 2025 ($252 Mil) to Dec. 2025 ($249 Mil) and declined from Dec. 2025 ($249 Mil) to Mar. 2026 ($228Mil).

United Therapeutics's annual other current assets increased from Dec. 2023 ($166 Mil) to Dec. 2024 ($170 Mil) increased from Dec. 2024 ($170 Mil) to Dec. 2025 ($249 Mil).


United Therapeutics Other Current Assets Related Terms


United Therapeutics Other Current Assets Historical Data

* Premium members only.

The historical data trend for United Therapeutics's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

United Therapeutics Other Current Assets Chart

United Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 100.40 219.20 166.20 169.70 248.90

United Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 131.10 229.70 252.20 248.90 228.00
UTHR
85GF Score
United Therapeutics Corp UTHR
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

United Therapeutics Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of $228 Mil mean?
United Therapeutics (UTHR) has a Other Current Assets of $228 Mil as of Mar. 2026. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on United Therapeutics.
Is United Therapeutics' Other Current Assets too high?
United Therapeutics' current Other Current Assets is $228 Mil. Overall, United Therapeutics has a GF Score™ of 85/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' Other Current Assets compare to VTRS and NBIX?
United Therapeutics' Other Current Assets of $228 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Drug Manufacturers company?
A good Other Current Assets depends on the Drug Manufacturers industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on United Therapeutics. United Therapeutics's current Other Current Assets is $228 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (UTHR) is currently considered Significantly Overvalued. The stock's GF Value™ is $386.77, compared to a current price of $547.25 — trading 41.5% above its estimated fair value. The current Other Current Assets is $228 Mil. United Therapeutics' overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For United Therapeutics (UTHR), the current Other Current Assets is $228 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is United Therapeutics (UTHR) Overvalued in 2026?

Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued. The current stock price of $547.25 is trading 41.5% above its estimated GF Value™ of $386.77. GuruFocus considers United Therapeutics to be Significantly Overvalued.

Key valuation signals for UTHR:

  • Other Current Assets: $228 Mil
  • GF Value™: $386.77 vs. price of $547.25 (41.5% above fair value)
  • GF Score™: 85/100 with 7 warning signs

No single metric tells the full story. See the UTHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


United Therapeutics Business Description

Other Exchanges UTH:GermanyU2TH34:Brazil
Address 1000 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
85GF Score

Get the complete analysis for UTHR

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$547.25
Price
$386.77
GF Value